Ongoing trials are testing several drugs (capmatinib, sotarasib, trastuzumab-deruxtecan and trastuzumab-emtasine) that are already used in clinical practice as a second line option for lung cancer and their benefit is not limited to the population with EGFR mutation (29–33). The gene discussed is EGFR; the disease is lung cancer.